38th week of 2010 patent applcation highlights part 37 |
Patent application number | Title | Published |
20100239561 | SURFACE SANITIZER FOR THE FOOD INDUSTRY BASED ON THREE NEW LACTIC ACID BACTERIA THAT HAVE ANTAGONISTIC ACTION AGAINST Listeria monocytogenes, THE MICROORGANISM THAT CAUSES LISTERIOSIS IN HUMANS - The present invention relates to a formulation useful to control | 2010-09-23 |
20100239562 | Kv CHANNELS IN NEURODEGENERATION AND NEUROPROTECTION - A family of potassium channels (Kv) are expressed in neurons when they are damaged. Blockers of these channels protect neurons from several different types of insults, whether due to disease or trauma. Furthermore, blockers of these channels promote neurite outgrowth in neural progenitor cells. These findings permit methods of treating as well as methods for identifying and developing drugs for neurological diseases where injury to neurons may occur. | 2010-09-23 |
20100239563 | PHARMACEUTICAL COMPOSITION FOR THE PROPHYLAXIS AND/OR TREATMENT OF VIRAL DISEASES - The invention relates to the use of at least one active substance for producing a pharmaceutical composition for the prophylaxis and/or treatment of at least one viral disease. It is characterized by active substance(s) which inhibit(s) either at least two kinases or at least one SEK kinase of a cellular signal transmission path such that virus multiplication is inhibited. | 2010-09-23 |
20100239564 | NOVEL HUMAN GROWTH FACTORS - The present invention relates to huXAG-1, huXAG-2 and huXAG-3 proteins which are novel human growth factors. In particular, isolated nucleic acid molecules are provided encoding the huXAG-1, huXAG-2 and huXAG-3 proteins. huXAG-1, huXAG-2 and huXAG-3 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of huXAG-1, huXAG-2 or huXAG-3 activity. Also provided are diagnostic and therapeutic uses of huXAG-1. huXAG-2 and huXAG-3. | 2010-09-23 |
20100239565 | METHODS OF TREATMENT OF SKIN ULCERS - Methods for treating and/or preventing skin ulcers are provided featuring administration of pharmaceutical compositions comprising inhibitors of activity or expression Of Lp-PLA | 2010-09-23 |
20100239566 | ENIGMA-MDM2 INTERACTION AND USES THEREOF - The present invention relates to Enigma (PDLIM7)-Mdm2 interaction and use thereof. More particularly, it may induce an effective apoptosis of cancer cells by inhibition of an Enigma expression or an Enigma activity which induces Mdm2 destabilization and p53 activity; it may assess the prognosis of anti-cancer therapy by determining that Enigma, which is induced by SRF, is overexpressed in cancer tissues with Mdm2; it may screen anti-cancer activity substances by to selecting a factor to inhibit specific binding between Enigma and Mdm2. Enigma-Mdm2 interaction and Enigma expression regulation may be utilized usefully for preventing cancers and developing therapeutic methods and anti-cancer agents. | 2010-09-23 |
20100239567 | Antibody Formulation - A formulation comprising a therapeutically effective amount of an antibody, optionally, not subjected to prior lyophilization, a buffer maintaining the pH in the range from about 4.5 to about 6.5, and an optional surfactant is described, along with uses for such a formulation. | 2010-09-23 |
20100239568 | DIAGNOSTICS AND TREATMENTS FOR TUMORS - Methods for the treatment of cancer with combination therapies that include anti-VEGF antibodies are provided. Methods for diagnosing resistant tumors are also provided. | 2010-09-23 |
20100239569 | Method Of Treating Disorders Of The Cardiovascular System And A Pharmaceutical Agent - The present application relates to a method of treating disorders of the cardiovascular system which includes administration of homeopathically potentized form of at least one antibody to an antigen, wherein the homeopathically potentized form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent capable of regulating cardiovascular disorders and pharmaceutical agents thereof. | 2010-09-23 |
20100239570 | MONCOLONAL AMYLOID BETA (ABETA) - SPECIFIC ANTIBODY AND USES THEREOF - A monoclonal antibody against beta-amyloid (ABeta) peptide is provided with unique immunological and biological properties useful in the immunotherapy of Alzheimer's disease. In addition, pharmaceutical compositions and kits comprising such antibody and mimics thereof in the treatment of neurological disorders such as Alzheimer's disease are described. | 2010-09-23 |
20100239571 | CD30 Binding Agents and Uses Thereof - This invention relates to CD30 binding agents and methods of using such binding agents for treating disease characterized by expression of CD30 antigen. | 2010-09-23 |
20100239572 | METHODS FOR TREATING AND PREVENTING GI SYNDROME AND GRAFT VERSUS HOST DISEASE - We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases. | 2010-09-23 |
20100239573 | METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Bb SPECIFIC ANTIBODIES - A process of inhibiting the adverse effects of alternative complement pathway activation products in a subject includes administering to the subject an amount of anti-factor Bb antibody effective to selectively inhibit formation of an alternative complement pathway activation products C3a, C5a, and C5b-9, and activation of neutrophils, monocytes, and platelets. | 2010-09-23 |
20100239574 | HIGH POTENCY RECOMBINANT ANTIBODIES AND METHOD FOR PRODUCING THEM - High potency antibodies, including immunologically active fragments thereof, having high kinetic association rate constants and optional high affinities are disclosed, along with methods for producing such antibodies. The high potency antibodies disclosed herein are of either the neutralizing or non-neutralizing type and have specificity for antigens displayed by microorganisms, especially viruses, as well as antigenic sites present on cancer cells and on various types of toxins, and the products of toxins. Processes for producing high potency neutralizing antibodies and increasing the potency of already existing neutralizing antibodies are also described. Methods of using said antibodies in the prevention and/or treatment of diseases, especially diseases induced or caused by viruses, are disclosed. | 2010-09-23 |
20100239575 | ANTI-CD40 ANTIBODIES AND USES THEREOF - The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies. | 2010-09-23 |
20100239576 | AMINO ESTER DERIVATIVES, SAILTS THEREOF AND METHODS OF USE - The present invention provides amino ester compounds, salts, and pharmaceutical formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans. | 2010-09-23 |
20100239577 | ANTI-GLYPICAN-3 ANTIBODY HAVING IMPROVED KINETICS IN PLASMA - A method of modulating the plasma half-life of anti-glypican 3 antibody, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody that has a plasma half-life that has been modulated, a method of preparing the anti-glypican 3 antibody and a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient are provided. Disclosed is a method of modulating the plasma half-life of anti-glypican 3 antibody by modifying an amino acid residue that is exposed on the surface of the anti-glypican 3 antibody; and anti-glypican 3 antibody that has a plasma half-life that has been modulated by amino acid residue modification, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody, and a method of preparing the anti-glypican 3 antibody and producing a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient. | 2010-09-23 |
20100239578 | MODULATION OF SIRP-ALPHA - CD47 INTERACTION FOR INCREASING HUMAN HEMATOPOIETIC STEM CELL ENGRAFTMENT AND COMPOUNDS THEREFOR - The invention relates to modulating the SIRPα-CD47 interaction in order to increase hematopoietic stem cell engraftment and compounds therefor. In some embodiments, there is provided isolated SIRPα and CD47 polypeptides, fragments and fusion proteins for enhancing hematopoietic stem cell engraftment. Further there is provided methods for increasing hematopoietic stem cell engraftment through administration of the above polypeptides. | 2010-09-23 |
20100239579 | CD47 Related Compositions and Methods for Treating Immunological Diseases and Disorders - Provide herein are fusion polypeptides that comprise a CD47 extracellular domain or a variant thereof that is fused to a Fc polypeptide. The fusion polypeptides are useful for treating an immunological disease or disorder in a subject according to the methods described herein. The fusion polypeptides are capable of suppressing immunoresponsiveness of an immune cell, inhibiting production of proinflammatory cytokines, including inhibiting immune complex-induced production of cytokines. | 2010-09-23 |
20100239580 | TACI-IMMUNOGLOBULIN FUSION PROTEINS FOR TREATMENT OF OPTIC NEURITIS - The invention relates to TACI-Immunoglobulin fusion proteins for the treatment of optic neuritis. | 2010-09-23 |
20100239581 | KIDNEY DISEASE TARGETS AND USES THEREOF - The present invention provides a method for diagnosing and detecting diseases associated with kidney. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in kidney diseases (KCAT) and antibodies binds to KCATs. The present invention provides that KCATs are used as targets for screening agents that modulates the KCAT activities. Further the present invention provides methods for treating diseases associated with kidney. | 2010-09-23 |
20100239582 | Dual Specificity Antibody Fusions - The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest. | 2010-09-23 |
20100239583 | ANTIBODIES AGAINST FLAGELLIN AND USES THEREOF - The present invention provides a novel class of monoclonal antibodies which have a high affinity, broad spectrum neutralizing reactivity to flagellin from various Gram-negative bacteria including, but not limited to, | 2010-09-23 |
20100239584 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3A AND X - The present invention relates to compounds derived from sugars which reproduce the epitopes of | 2010-09-23 |
20100239585 | Antibodies Against Mammalian Metapneumovirus - The present invention provides antibodies that immunospecifically bind to a polypeptide of a mammalian metapneumovirus, compositions comprising said antibodies, and methods for producing such antibodies. In particular, the invention provides monoclonal antibodies that immunospecifically bind to the F protein of human metapneumovirus and that neutralize human metapneumovirus. The invention also provides antibodies that cross-react with both the F protein of a mammalian metapneumovirus and the F protein of a mammalian respiratory syncytial virus and that neutralize both viruses. Further, the invention provides recombinant antibodies, such as humanized antibodies, against mammalian metapneumovirus, and methods for producing such recombinant antibodies. The invention further provides methods for treating, managing, ameliorating symptoms of and/or preventing infections with mammalian metapneumovirus, such as human metapneumovirus. The invention also provides antibodies that immunospecifically bind the F protein of avian pneumovirus. Antibodies that immunospecifically bind the F protein of avian pneumovirus are useful in the diagnosis and treatment of infections with avian pneumovirus. | 2010-09-23 |
20100239586 | PROCALIN POLYPEPTIDES, ANTIGENS, AND METHODS OF USE - The disclosure provide polypeptides and polynucleotides encoding | 2010-09-23 |
20100239587 | ErbB Interface Peptidomimetics And Methods Of Use Thereof - Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are described. Methods of using such antibodies, peptides, and mimetics in therapeutic, prophylactic, imaging and diagnostic applications are disclosed. | 2010-09-23 |
20100239588 | THE FUNCTIONAL EPITOPE OF OSTEOPONTIN, THE ANTI-OSTEOPONTIN MONOCLONAL ANTIBODY AND USE THEREOF - The present invention discloses the functional epitope of osteopontin; the anti-osteopontin monoclonal antibody and immune conjugate raising against the functional epitope and their use for preparing anti-tumor drug. The present invention also discloses the DNA sequence encoding the monoclonal antibody, the vector and host cell containing the DNA sequence. The monoclonal antibody and immune conjugate of present invention can also be used to detect OPN. Through inhibiting OPN, the monoclonal antibody or immune conjugate of present invention can remedy or respite autoimmune diseases and protect correlative tissues, so they can be used to remedy autoimmune diseases. | 2010-09-23 |
20100239589 | Methods and Compositions for Ameliorating Diabetes and Symptoms Thereof - The present invention relates generally to the Tlr4 signaling pathway specifically in the hematopoietic system and its contribution to insulin resistance of liver and adipose tissue. The hematopoietic component expressing Tlr4 is a principle propagator of immune signaling and results in insulin resistance. Furthermore, disclosed herein are methods and compositions for treating or preventing disorders associated with insulin resistance using a Tlr4 antagonist. | 2010-09-23 |
20100239590 | JOINT DESTRUCTION BIOMARKERS FOR ANTI-IL-17A THERAPY OF INFLAMMATORY JOINT DISEASE - Novel methods and drug products for treating inflammatory joint diseases such as rheumatoid arthritis and associated arthritides are disclosed. The methods and products employ various serum markers of bone and cartilage metabolism or destruction, including cartilage oligomer matrix protein (COMP) and Receptor activator of NFB ligand (RANKL), as biomarkers to assess the effect of IL-17A antagonists on joint destruction in inflammatory joint diseases. | 2010-09-23 |
20100239591 | MONOCLONAL ANTIBODY FOR APP - The invention relates to a novel peptide, polypeptide or monoclonal antibody for use in the treatment of conditions characterised by elevated levels of β-amyloid (Aβ 39-43 amino acid peptide) in a subject, especially Alzheimer's Disease. The invention particularly relates to an amyloid precursor protein (APP)-binding polypeptide which, when administered outside an APP-expressing cell, reduces the release of Aβ 39-43 by the cell. | 2010-09-23 |
20100239592 | METHODS OF ANALYSIS AND DETECTING MOLECULAR DEFECTS IN TRANSCOBALAMIN I DEFICIENCY - The present invention provides methods, compositions, and kits for detecting TC I deficiency in individuals with low serum cobalamin levels. Methods for detecting TCN1 mutations and/or the TC I isoforms or products of TCN1 mutations are useful for detecting and diagnosing those who have TC I deficiency and thereby can be said to have TC I deficiency instead of cobalamin deficiency. | 2010-09-23 |
20100239593 | RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM - The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them. | 2010-09-23 |
20100239594 | Compositions and methods for production of immunoglobulins - Provided are oligonucleotides for isolating human antibody cDNAs from cells or cell lines, such as hybridomas. The invention also provides cDNAs that encode at least one provided CDR of a heavy chain or a light chain of a human monoclonal antibody that binds to | 2010-09-23 |
20100239595 | EQUINE ANTIBODIES AGAINST BACILLUS ANTHRACIS FOR PASSIVE IMMUNIZATION AND TREATMENT - Disclosed are compositions and methods for treating a subject infected with | 2010-09-23 |
20100239596 | GRP78 AND TUMOR ANGIOGENESIS - Methods of preventing or reducing tumor angiogenesis in a subject, comprising administering to the subject one or more agents that inhibit expression or activity of GRP78 are provided. Also provided are methods of sensitizing tumor blood vessels to a chemotherapeutic agent comprising administering to the subject one or more agents that inhibit expression or activity of GRP78. Provided is also a method of reducing tumor microvessel density in a subject, comprising selecting a subject with a tumor, wherein the subject is in need of reduction of tumor microvessel density, and administering to the subject one or more agents that inhibit expression or activity of GRP78. | 2010-09-23 |
20100239597 | Anti-ADDL monoclonal antibody and use thereof - The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42. | 2010-09-23 |
20100239598 | POLYPEPTIDES AND ANTIBODIES DERIVED FROM CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND USES THEREOF - Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or by targeting cells using a fusion molecule that includes a CD200-targeting portion. The therapy includes the administration of novel antibodies, functional fragments thereof or fusion molecules containing portions thereof. | 2010-09-23 |
20100239599 | Vaccine Peptide Combinations Against Cat Allergy - The present invention relates to compositions comprising peptides for preventing or treating allergy to cats, and in particular to optimal combinations of peptides. | 2010-09-23 |
20100239600 | CONJUGATE PURIFICATION - This application relates to methods for the purification of saccharide antigen-carrier protein conjugates. In particular, the invention provides a method for purifying saccharide antigen- carrier protein conjugates from free carrier protein, such as CRM1 97, using hydroxyapatite. The invention further relates to methods of preparing vaccines, using this method. | 2010-09-23 |
20100239601 | METHOD OF IMMUNIZING HUMANS AGAINST SALMONELLA TYPHI USING A VI-REPA CONJUGATE VACCINE - This invention relates to conjugates of the Vi polysaccharide of | 2010-09-23 |
20100239602 | GRIFOLA FRONDOSA-DERIVED SUBSTANCE HAVING ANTI-INFLUENZA VIRUS ACTIVITY AND METHOD FOR PRODUCING THE SAME - This invention is intended to discover a fraction having strong anti-influenza virus activity via Mφ activation in the | 2010-09-23 |
20100239603 | Combinations of Botanical Extracts for Promoting Cardiovascular Health - A blood lipid lowering agent that functions through a same mechanism as berberine (e.g. berberine, one or more pharmacologically acceptable salts of berberine or a mixture thereof) and a blood lipid lowering agent that functions through a different mechanism than berberine (e.g. phytosterols, phytostanols, esters thereof or mixtures thereof) act synergistically to improve blood lipid profiles, for example, lowering total cholesterol, LDL-C or nonHDL-C, and triglyceride, and increasing the ratio of HDL-C to nonHDL-C. The two may be used in combination to treat or reduce the chance of contracting cardiovascular disease, hyperlipidemia, atherosclerosis, coronary heart disease, angina, cerebrovascular disease, stroke, overweight or obesity, diabetes, insulin resistance, hyperglycemia, hypertension, arrhythmia, diseases of the central nervous system, diseases of the peripheral nervous system and/or inflammation. The blood lipid lowering agent that functions through a same mechanism as berberine, with or without the blood lipid lowering agent that functions through a different mechanism than berberine, may also be used to control weight. | 2010-09-23 |
20100239604 | VACCINE COMPRISING STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE CONJUGATES - The present invention relates to an immunogenic composition comprising | 2010-09-23 |
20100239605 | Recombinant Rhinovirus Vectors - The invention provides recombinant rhinovirus vectors including, for example, influenza virus antigens. Also provided by the invention are corresponding pharmaceutical compositions and methods. | 2010-09-23 |
20100239606 | Two-Step Temperature Profile for the Propagation of Viruses - The present invention provides a method for the production of a virus. The method includes providing a host cell that has been infected by the virus and cultivating the infected host cell at two different temperatures. The virus produced by the cultivation steps is subsequently collected. By using the dual temperature cultivation process, high titer and improved purity can be obtained. | 2010-09-23 |
20100239607 | COMPOSITIONS FOR INDUCING IMMUNE RESPONSES - The invention provides, inter alia, immunogenic compositions comprising a first antigen, at least two adjuvants, wherein a first adjuvant comprises a polymer derived from poly(lactides) and/or poly(lactide-co-glycolides), and wherein a second adjuvant comprises an imidazoquinoline, wherein said first antigen is encapsulated within, adsorbed or conjugated to, co-lyophilized or mixed with said first adjuvant, and a pharmaceutically acceptable excipient, wherein said composition elicits a cellular immune response when administered to a vertebrate subject. The invention also provides methods of producing immunogenic compositions, methods for producing a cytotoxic-T lymphocyte (CTL) response in a vertebrate subject, and methods of immunization. | 2010-09-23 |
20100239608 | PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS - The present invention relates to a pharmaceutical composition containing an mRNA that is stabilised by sequence modifications in the translated region and is optimised for the translation. The pharmaceutical composition according to the invention is particularly suitable as an inoculating agent as well as a therapeutic agent for tissue regeneration. In addition a process is described for determining sequence modifications that serve for the stabilisation and translation optimisation of mRNA. | 2010-09-23 |
20100239609 | Formulation of Sugar Solutions for Continuous Ultracentrifugation for Virus Purification - The present invention provides a method for purification of a virus or virus antigen comprising providing a virus preparation and centrifugation of said virus preparation in a gradient of a sugar established by the addition of two or more buffered sugar layers of different concentration. The method leads to higher yields and reduces unwanted aggregation of the virus or virus antigen by increasing the volume of the peak pool. | 2010-09-23 |
20100239610 | INFLUENZA VIRUS-LIKE PARTICLES (VLPS) COMPRISING HEMAGGLUTININ PRODUCED WITHIN A PLANT - A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of influenza HA in plants and the purification by size exclusion chromatography. The invention is also directed towards a VLP comprising influenza HA protein and plants lipids. The invention is also directed to a nucleic acid encoding influenza HA as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines. | 2010-09-23 |
20100239611 | Combination adjuvant formulation - Methods and compositions for enhancing an immune response to a selected antigen are described. The methods are useful for the treatment and prevention of microbial infections, such as infections caused by bacteria, viruses, fungi and parasites. The methods and compositions include host defense peptides, polyphosphazenes and immunostimulatory sequences to enhance the immune response to a coadministered antigen. | 2010-09-23 |
20100239612 | Method of Immunization Against the 4 Serotypes of Dengue Fever - The invention relates to a method for inducing protection against the 4 serotypes of dengue fever in a patient, comprising:
| 2010-09-23 |
20100239613 | ATTENUATED EHRLICHIOSIS VACCINE - The present invention relates to an attenuated strain of | 2010-09-23 |
20100239614 | Isolation and Purification of P. Falciparum Merozoite Protein-142 Vaccine - In this application is the expression and purification of a recombinant | 2010-09-23 |
20100239615 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF LUNG CANCER - Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer. | 2010-09-23 |
20100239616 | CONTROLLED ACTIVATION INGESTIBLE IDENTIFIER - Controlled activation identifiers for use in ingestible compositions, such as pharma-informatics enabled compositions, are provided. The identifiers include a controlled activation element that provides for activation of the identifier in response to the presence of a predetermined stimulus at a target site of interest. The invention finds use in a variety of different applications, including but not limited to, monitoring of therapeutic regimen compliance, tracking the history of pharmaceutical agents, etc. | 2010-09-23 |
20100239617 | MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE - The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection. | 2010-09-23 |
20100239618 | TOOTHPASTE - The present invention relates to a toothpaste comprising one or more micronized unencapsulated peroxide compounds with improved properties with regard to cleaning and visual brightening of natural teeth, false teeth and/or polymer fillings of teeth; to its production and use. | 2010-09-23 |
20100239619 | Semi-permanent color for application to the skin and applicators therefor - A semi-permanent skin colorant patch provides a vehicle for transferring color to the skin. The color is water insoluble and remains on the skin for several days unless removed by a solvent. Generally, the semi-permanent skin colorant patch has a matte surface film with a water soluble slip layer and decal paper on one side. The other side has a pressure sensitive adhesive layer on which a semi-permanent color is printed. When the decal paper and slip layer are wetted and pressure is applied, the matte surface film and semi-permanent color are adhered to the skin. Thereafter, the decal paper and slip layer are discarded. In a second embodiment, an applicator having a fibrous tip and a hollow body receives semi-permanent color cartridge refills. The semi-permanent skin colorant can come in different shades and colors and has applications as lip colorant, eyeliner, eye shadow, foundation and blush. | 2010-09-23 |
20100239620 | MONODISPERSE PARTICLES - The present invention relates to novel monodisperse particles, which comprise at least one broad spectrum absorber contrast agent and/or at least one precursor of a broad spectrum absorber contrast agent, which is encapsulated in the monodisperse particle, novel colourant compositions, to uses thereof in colouring a substrate and to substrates that are coloured (at least in part) using the colourant compositions. | 2010-09-23 |
20100239621 | GEL SHEET AND COSMETIC PREPARATION IN SHEET FORM USING THE SAME - A gel sheet including a hydrogel, the hydrogel including at least 50 parts by mass of water-soluble divalent metal salt with respect to 100 parts by mass of anionic polymer compound is provided. | 2010-09-23 |
20100239622 | DETERGENT PRINTED FILM - The present invention discloses a water-soluble detergent printed film comprising a film support and at least one print, being printed thereon and/or therein said film, said film is a water-soluble detergent adapted for effective cleansing of various human body and goods cleaning. The present invention also discloses a method of producing a water-soluble detergent printed film, comprising forming a detergent film; and, printing the same with at least one print. | 2010-09-23 |
20100239623 | Styling Agent - Cosmetic agent for temporarily deforming keratin fibers, comprising a polysilicic acid in a cosmetically acceptable carrier, wherein the polysilicic acid is coated with at least one copolymer A formed from at least one monomer A1 according to Formula (A1) | 2010-09-23 |
20100239624 | CLEANSING LOTION WITH MOISTURISING, PROTECTING AND ODOR CONTROLLING AGENTS AND CLOTH COMPRISING SAID LOTION - The invention relates to a soothing lotion, which cleanses, moisturizes and protects the skin and controls odor from feces and urine on skin. The invention also relates to a cloth comprising said lotion. | 2010-09-23 |
20100239625 | TRANSPARENT ANTIMICROBIAL FACE MASK - A mask for being worn over the nose and mouth of a wearer, and a panel having sufficient transparency to permit visual observation of the mouth of the wearer. The panel is formed from first and second overlying transparent, pleated films perforated with elongate slits sized to permit two-way transit of gases, but not liquids, under atmospheric pressure. The first and second films each include a multitude of projections for maintaining between the first and second films a multitude of tortuous flow paths for permitting respiratory gas flow through the panel. | 2010-09-23 |
20100239626 | PROPANEDIOL DELIVERY SYSTEMS - A biodelivery system has been found which increases the efficiency and effectiveness of introducing antimicrobial compounds into complex biofilm matrices through the use of liposome carriers, thereby removing the biofouling in industrial water bearing systems, including piping, heat exchanges, condensers, filtration systems and fluid storage tanks. | 2010-09-23 |
20100239627 | QUARTERNARY AMMONIUM SALTS DELIVERY SYSTEMS - A biodelivery system has been found which increases the efficiency and effectiveness of introducing antimicrobial compounds into complex biofilm matrices through the use of liposome carriers, thereby removing the biofouling in industrial water bearing systems, including piping, heat exchanges, condensers, filtration systems and fluid storage tanks. | 2010-09-23 |
20100239628 | PRODUCT FOR WATER TREATMENT - A product for water treatment includes a plurality of bioceramic materials, in which at least one bioceramic material is chosen from among the following: Alkali Energy Ceramic Ball, Antibacterial Pellet, Far Infrared Ceramic Ball, and may also include Mineral Ceramic Ball. | 2010-09-23 |
20100239629 | Delivery system for delivering bioactive materials - A delivery system for delivering bioactive materials as an aqueous nanoparticle dispersion of a water soluble matrix of polyvinylpyrrolidone (PVP) polymer and copolymers thereof, and an anionic surfactant. | 2010-09-23 |
20100239630 | PHOSPHONIUM SALTS DELIVERY SYSTEMS - A biodelivery system has been found which increases the efficiency and effectiveness of introducing antimicrobial compounds into complex biofilm matrices through the use of liposome carriers, thereby removing the biofouling in industrial water bearing systems, including piping, heat exchanges, condensers, filtration systems and fluid storage tanks. | 2010-09-23 |
20100239631 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF - The present invention relates to thiopyrimidine-based compounds that are inhibitors of protein kinases including JAK kinases. In particular, the compounds are selective for JAK1, JAK2 or JAK3 kinases and combinations thereof such as JAK1 and JAK2. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases and vascular diseases. | 2010-09-23 |
20100239632 | DRUG DEPOTS FOR TREATMENT OF PAIN AND INFLAMMATION IN SINUS AND NASAL CAVITIES OR CARDIAC TISSUE - Effective treatments of pain and/or inflammation are provided. Through the administration of a biodegradable drug depot film, patch, strip or sponge being implantable at or near a cardiac tissue or within a nasal or sinus cavity, one can reduce, prevent or treat pain and/or inflammation. | 2010-09-23 |
20100239633 | IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS - IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases. | 2010-09-23 |
20100239634 | COMPOSITIONS AND METHODS FOR PROMOTING BONE FORMATION - A method for promoting bone formation is provided. More specifically, a method for promoting bone formation by promoting osteoclast formation is provided. In one embodiment, an implant comprising an implantable material and an osteoclast stimulating substance is provided. | 2010-09-23 |
20100239635 | DRUG DELIVERY MEDICAL DEVICE - Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on said substrate, wherein said coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within said coating and on said substrate until the implantable device is deployed at an intervention site inside the body of a subject and wherein upon deployment of said medical device in the body of said subject a portion of said pharmaceutical agent and/or active biological agent is delivered at said intervention site along with at least a portion of said polymer and/or a at least a portion of said pharmaceutical carrying agents. | 2010-09-23 |
20100239636 | Methods and Devices for Delivering Therapeutic Agents to Target Vessels - Methods of preparing devices for delivering at least one therapeutic agent to a target vessel in a mammal, the devices prepared by such methods, and uses of such devices for delivering a therapeutic agent, such as an antiproliferative agent, to a target vessel. | 2010-09-23 |
20100239637 | CONTACT LENS DRUG DELIVERY DEVICE - The present invention relates generally to devices and methods for administering one or more active agents to the eye of a human or animal patient in need thereof, and more particularly to devices for application to the cornea which release active agent to the eye in a controlled manner. | 2010-09-23 |
20100239638 | CHEWABLE SOFT CAPSULE HAVING IMPROVED INGESTION PROPERTY AND METHOD FOR PRODUCING SAME - A soft capsule in which a shell is filled with fill material, and the fill material is in a solid or semi-solid form at room temperature. The soft capsule may be a chewable capsule, and the fill material may comprise a low melting point additive. The content of the low melting point additive may be 10% or more with respect to the total weight of the fill material, and may have a melting point of about 20 to 50° C. The low melting point additive may be selected from the group consisting of chocolate base, lard, coconut oil and macrogol (polyethylene glycol) as well as a combination thereof. | 2010-09-23 |
20100239639 | MEDICATED PATCH - A conventional medicated patch containing an anti-inflammatory agent causes a dermatitis or the like on rare occasion by excess irradiation with light. For overcoming the problem, a medicated patch is provided, which comprises an anti-inflammatory agent, BM-DBM as an ultraviolet absorber, and hexyl laurate as an agent for accelerating the migration of the ultraviolet absorber into the skin in an adhesive base material thereof. | 2010-09-23 |
20100239640 | SKIN-DERIVED PRECURSOR CELLS AND USES THEREOF - The invention features methods of inducing hair follicle formation in a mammal by transplantation of skin-derived precursors (SKPs) and keratinocytes into the skin of the mammal. The invention also features compositions and kits including SKPs and keratinocytes. In other aspects, the invention features methods for producing dermal sheets from SKPs, methods for using such sheets and dermal sheets produced by SKPs. | 2010-09-23 |
20100239641 | Warming vapor pad - A warming vapor pad to treat respiratory syncytial virus infections in babies, children and adults includes a fabric impregnated with a topical ointment providing medicated vapors to relieve a user's cough, with the fabric being superimposed on an elastic thermal wrap for application as a single layer on the user's chest. | 2010-09-23 |
20100239642 | COATING COMPOSITIONS - Described are coating compositions for marking substrates comprising a) a solvent, b) a salt of a phosphorus or boron containing acid and an amine or imine, c) a salt of a non-phosphorus and non-boron containing acid and an amine or imine, d) a binder, and e) optionally additional ingredients, their manufacture and use, wherein the above-mentioned salts can also be present in an encapsulated form as a kind of pseudo-pigment. Substrates coated by the above compositions can be marked by laser irradiation. | 2010-09-23 |
20100239643 | ANTI-ITCH SHEET - The present invention provides an anti-itch sheet suitable for curing and relieving itching caused by an insect bite or sunburn based on a novel finding, the anti-itch sheet comprising a sealing layer, and a fixing layer on a skin-contacting side of the sealing layer for facilitating the application of the sealing layer to the skin. | 2010-09-23 |
20100239644 | Method of Preparing Polymeric Adhesive Compositions Utilizing the Mechanism of Ineraction Between the Polymer Components - A method of selecting components for use in water-absorbing pressure-sensitive adhesive compositions is provided. The method involves selecting a film-forming polymer, a ladder-like non-covalent crosslinker that is capable of forming a ladder-like interpolymer complex with the film-forming polymer selected, and selecting a carcass-like non-covalent crosslinker that is capable of forming a carcass-like complex with at least one of the film-forming polymer selected or the ladder-like non-covalent crosslinker selected. The adhesive hydrogels provide high adhesion in a swollen state and bridge the gap between conventional pressure sensitive adhesives and bioadhesives. Methods for preparing and using the resulting compositions are also disclosed. | 2010-09-23 |
20100239645 | Methods and Compositions for Wound Healing - Glycerophosphate salts have been found to hasten the healing of wounds and minimize the formation of scars, particularly when it is first applied to a wound about 0 to about 7 days after the wound is inflicted. Methods and compositions are provided for treating wounds using a composition comprising an effective amount of glycerophosphate salt. In particular, methods are provided for treating wounds using calcium glycerophosphate (CGP), for accelerating the healing process, reducing pain and scar formation, and for the cosmetic reducing, excision, erasure and/or complete repair of scars (scar revision). | 2010-09-23 |
20100239646 | Sublingual methotrexate and methotrexate patches - Several major new inflammatory diseases that respond to methotrexate are identified in this Invention. These newly identified indications that respond to methotrexate include a number of cardiovascular diseases, coronary heart disease and stroke. To optimize and improve therapeutic effectiveness, therapeutic responses and to minimize toxicity new sublingual dosage units and patches of methotrexate are taught in this Invention for direct delivery of the drug to the blood stream bypassing absorption through the human gut. The practice of this invention as provided herein should result in significant improvement of the therapeutic index of methotrexate in the treatment of a number of painful, crippling, disfiguring, and fatal diseases. This Invention therefore addresses an unmet need to treat the above diseases for which there are no curative treatments are available at the present time. The use of sublingual methotrexate or methotrexate patches to prevent, treat or reverse cardiovascular diseases, coronary heart disease and stroke is new and the practice of this invention should result in very significant therapeutic improvements and commercial benefits. | 2010-09-23 |
20100239647 | PHOTORESPONSIVE IONOGEL - A photoresponsive ionogel comprising a photo-responsive polymer polymerised within an ionic liquid matrix is described. This solid-state electrolyte material maintains its ionic liquid characteristics but these characteristics can be altered upon irradiation of the gel with light of a particular wavelength. By suitably configuring the ionogel through the incorporation of specific ions within the gel it is possible to cause dramatic changes in properties of the ionogel such as viscosity, conductivity, acidity, basicity and polarity using light as the stimulus. | 2010-09-23 |
20100239648 | SELF-LOCATING, MULTIPLE APPLICATION, AND MULTIPLE LOCATION MEDICAL PATCH SYSTEMS AND METHODS THEREFOR - A medical patch system has a first medical patch including an outer locating ring secureable to a surface and an inner patch, separable from the outer locating ring, disposed within the outer locating ring. The medical patch system includes a second medical patch adapted for insertion into the central area bounded by the outer locating ring after the inner patch is separated from the outer locating ring. The second medical patch includes a second outer locating ring secureable to the surface, and a second inner patch section, separable from the second outer locating ring, disposed within a second central area bounded by the second outer locating ring. The first and second outer locating rings have adhesive layers for securing the outer locating rings to a surface. The adhesive layers on the respective outer locating rings have different sizes, shapes or patterns to minimize skin irritation. | 2010-09-23 |
20100239649 | Tumor Suppressor Factor - The present invention relates to a tumour suppressor gene, termed HLS-5 and the amino acid sequence that it encodes. The present invention also relates to the use of HLS-5 in regulating cell growth. | 2010-09-23 |
20100239650 | ISOTHIAZOLIN BIODELIVERY SYSTEMS - A biodelivery system has been found which increases the efficiency and effectiveness of introducing antimicrobial compounds into complex biofilm matrices through the use of liposome carriers, thereby removing the biofouling in industrial water bearing systems, including piping, heat exchanges, condensers, filtration systems and fluid storage tanks. | 2010-09-23 |
20100239651 | NITRILOPROPIONAMIDE DELIVERY SYSTEMS - A biodelivery system has been found which increases the efficiency and effectiveness of introducing antimicrobial compounds into complex biofilm matrices through the use of liposome carriers, thereby removing the biofouling in industrial water bearing systems, including piping, heat exchanges, condensers, filtration systems and fluid storage tanks. | 2010-09-23 |
20100239652 | IMMUNOLIPOSOMES FOR TREATMENT OF CANCER - The present invention relates to immunoliposomes for multiple treatment of human patients suffering from cancer, particularly a cancer represented by a locally advanced or metastatic tumor and to compositions used in said method. The invention further relates to the use of immunoliposomes for the treatment of multi-drug resistance in cancer therapy. | 2010-09-23 |
20100239653 | PHARMACEUTICAL PREPARATIONS AND METHODS FOR INHIBITING TUMORS - The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH). In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer. The anticancer drug of the latter mixture may be one selected from the group of drugs including mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof. | 2010-09-23 |
20100239654 | VESICULAR PHOSPHOLIPID GELS COMPRISING PROTEINACEOUS SUBSTANCES - The present invention relates to a pharmaceutical composition for sustained release of a pharmaceutically active compound, the composition comprising a vesicular phospholipid gel. More particularly, the invention relates to a pharmaceutical composition comprising at least one proteinaceous substance as the pharmaceutically active compound in encapsulated form, the at least one proteinaceous substance being a biologically active protein, peptide or polypeptide. Furthermore, the present invention relates to a method for the production of said pharmaceutical composition comprising dual asymmetric centrifugation and to the use of said pharmaceutical composition for immunotherapy and/or for stimulating selective tissue regeneration in the treatment of surgical defects in the course of surgical interventions. | 2010-09-23 |
20100239655 | TAURINE-BASED COMPOSITIONS AND THERAPEUTIC METHODS - Taurine and derivatives thereof may be used in conjunction with agents that activate or up-regulate the Taurine Transporter so as to enhance hydration of the skin and repair the skin bather, prevent apoptosis and oxidative damage in the skin, and heal or prevent photo-induced skin damage. The presence of biogenic taurine or taurine derivatives in tissues and/or body fluids can be used as a biomarker for tissue trauma. Detection and/or quantification of such biogenic taurine or derivatives form the basis for an assay for determining the presence and/or extent of tissue damage. | 2010-09-23 |
20100239656 | EGFR/NEDD9/TGF-BETA INTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS - Compositions and methods for the treatment and diagnosis of cancer are disclosed. | 2010-09-23 |
20100239657 | COMPOSITE FOR LIVER-SPECIFIC DELIVERY AND RELEASE OF THERAPEUTIC NUCLEIC ACIDS OR DRUGS - The inventive composite having a nanoscale particle size can specifically deliver therapeutic nucleic acids or drugs to the liver and selectively release them into hepatic cells to manifest potent therapeutic effects without inducing any enzymatic abnormalities or pathological damage to the normal liver function, when administered together with the therapeutic agents. | 2010-09-23 |
20100239658 | GALLIUM NITRATE FORMULATIONS - The present invention relates to stable pharmaceutical formulations that include a delivery agent and/or pharmaceutically acceptable salt thereof. | 2010-09-23 |
20100239659 | SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTI-CANCER AGENTS - The invention provides amphiphilic biocompatible copolymers which have a hydrophilic backbone and pendant hydrophobic groups. The polymers form nanoscale molecular aggregates in aqueous environments, which have hydrophobic interiors within which anticancer drugs may be solubilized. The polymers optionally feature attached antibodies, receptor ligands, and other targeting moieties which mediate adherence of the drug-carrying aggregates to targeted cancer cells. | 2010-09-23 |
20100239660 | PRODUCT AND USE OF OMEGA-3S MATCHING HUMAN TISSUE RATIOS FOR TREATMENT OF INFLAMMATORY AND OTHER CONDITIONS - The present invention relates to a product and method for delivering of DHA and EPA in need of omega-3 treatment. It involves administering a liquid formulation such as an oil containing DHA and EPA in a ratio that closely resembles the ratio of DHA and EPA in the human body. The result is a composition that performs as good or better than fish based compositions containing omega-3 fatty acids and can be dosed into smaller volumes when administering mega doses of 1000-2000 mg of DHA to a selected patient. | 2010-09-23 |